Company Encyclopedia
View More
name
Korro Bio
KRRO.US
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson’s disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications.
1.905 T
KRRO.USMarket value -Rank by Market Cap -/-

Financial Score

16/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking286/395
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-63.46%E
    • Profit Margin-1199.53%E
    • Gross Margin-870.55%E
  • Growth ScoreD
    • Revenue YoY0.00%C
    • Net Profit YoY-0.69%C
    • Total Assets YoY-33.67%E
    • Net Assets YoY-44.87%E
  • Cash ScoreD
    • Cash Flow Margin-8.34%D
    • OCF YoY0.00%C
  • Operating ScoreE
    • Turnover0.04E
  • Debt ScoreB
    • Gearing Ratio38.70%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    6 Interesting Tax Selling Stocks For A Possible January Bounce

    The article discusses a contrarian investment strategy of buying stocks that have fallen sharply by year-end due to tax-loss selling. This approach aims to exploit temporary price distortions, with potential rebounds in January as selling pressure eases. The strategy focuses on stocks down over 75%, selling below book value and cash per share, with market caps above $65 million. Six stocks identified as potential candidates for a January bounce include Atyr Pharma, Korro Bio, New Fortress Energy, Pliant Therapeutics, Vivid Seats, and Teads Holding.

    Talkmarkets·
    US
    NFE
    -5.46%
    US
    SEAT
    +6.27%
    US
    KRRO
    0.00%
    Talkmarkets·
    US
    NFE
    -5.46%
    US
    SEAT
    +6.27%
    US
    KRRO
    0.00%

    Why Korro Bio (KRRO) Is Down 80.0% After Restructuring, Clinical Trial Miss, and CMO Resignation

    Korro Bio's stock fell 80% following a major restructuring, a clinical trial that failed to meet efficacy expectations, and the resignation of its Chief Medical Officer. The company announced a 34% workforce reduction and paused its collaboration with Novo Nordisk. These changes, along with mixed trial results, have increased uncertainty and risk in Korro Bio's investment narrative, affecting short-term catalysts and future clinical outcomes. Despite these challenges, some community members see potential value in the stock, with fair value estimates ranging widely.

    Simplywall·
    US
    KRRO
    0.00%
    Simplywall·
    US
    KRRO
    0.00%

    RBC Capital downgrades Korro Bio (KRRO) to a Hold

    RBC Capital analyst Luca Issi downgraded Korro Bio (KRRO) to a Hold with a price target of $8.00, while the stock closed at $6.50. Cantor Fitzgerald also rated it as Hold, but Clear Street initiated coverage with a Buy rating on October 30. Issi, who covers the Healthcare sector, has an average return of 6.7% and a 41.16% success rate on recommended stocks.

    Tip Ranks·
    US
    KRRO
    0.00%
    Tip Ranks·
    US
    KRRO
    0.00%

    Korro Bio (NASDAQ:KRRO) Releases Earnings Results, Beats Estimates By $0.69 EPS

    Korro Bio (NASDAQ:KRRO) reported quarterly earnings of ($1.92) per share, beating the consensus estimate of ($2.61) by $0.69. Despite the positive earnings surprise, shares fell 4.2% to $31.42. Analysts have mixed ratings, with a consensus "Buy" rating and a price target of $86.83. Hedge funds have adjusted their holdings, with notable increases from Vanguard and Geode Capital. Korro Bio focuses on genetic medicines, with its lead product KRRO-110 in preclinical trials for Alpha-1 Antitrypsin Deficiency.

    Market Beat·
    US
    KRRO
    0.00%
    Market Beat·
    US
    KRRO
    0.00%

    Korro Bio stock fell after missing expectations in early stage KRRO-110 trial

    Korro Bio's stock fell after the KRRO-110 trial failed to meet expected protein levels for alpha-1 antitrypsin deficiency treatment, despite producing some functional protein.

    MSN·
    US
    KRRO
    0.00%
    MSN·
    US
    KRRO
    0.00%
    © 2025 Longbridge｜Disclaimer